Category Archives: Global News Feed

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $125.0 million. The offering included new investors, Braidwell and Suvretta Capital Management’s Averill strategy, as well as participation from existing stockholders.

See the article here:
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value.   The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committee includes ARCA Board Chairman Robert E. Conway (chair), and Board members Linda Grais, M.D. and Anders Hove, M.D.

More here:
ARCA biopharma Establishes Special Committee of the Board of Directors

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference on Thursday, April 21st at 11:30 a.m. ET.

Go here to see the original:
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now be offering 50% more doses for patient use Monday-Friday beginning the week of May 1, 2022.

The rest is here:
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022, at 9:30 AM ET.

Follow this link:
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

COPENHAGEN, Denmark, April 5, 2022 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:

The rest is here:
Resolutions of the Annual General Meeting 2022 of Bavarian Nordic A/S

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Link:
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted through advance voting pursuant to temporary regulations. Therefore, it will not be possible to attend this year’s Meeting in person or by proxy.

Read more here:
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics

Atreca Announces Licensing Agreement with Zymeworks

Read the original post:
Atreca Announces Expansion of Preclinical Pipeline

Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card

Read this article:
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders